Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.
The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.
Galli
Luisa
L
Departments of Pediatrics, University of Florence, Florence, Italy.
Novelli
Andrea
A
Chiappini
Elena
E
Gervaso
Paola
P
Cassetta
Maria Iris
MI
Fallani
Stefania
S
de Martino
Maurizio
M
D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000151:congenital / Q000188:drug therapy* / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010865:Pilot Projects; D000077562:Valganciclovir; D019562:Viral Load
D000998:Antiviral Agents; D004279:DNA, Viral; D000077562:Valganciclovir; D015774:Ganciclovir